Operates retail drugstores under the Walgreens and Duane Reade brands in the United States. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
No real growth (5% a year). Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
An investor who bought at the very peak is down 79% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The company sells $148B a year; the problem isn’t sales — it’s costs running above that number.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
It pays out $1.00 per share each year — regular cash for whoever holds the stock.
A loss of $8.6B against $148B in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.